PCM
PBYI icon

Proxima Capital Management’s Puma Biotechnology PBYI Stock Holding History

Proxima Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-52,000
Closed -$1.06M – 36
2018
Q4 		$1.06M Sell
52,000
-5,285
-9% -$159K 1% 25
2018
Q3 		$2.63M Buy
57,285
+10,285
+22% +$496K 1.75% 19
2018
Q2 		$2.78M Buy
47,000
+17,000
+57% +$985K 1.65% 19
2018
Q1 		$2.04M Buy
+30,000
New +$2.25M 1.12% 27

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Proxima Capital Management's PBYI Position: Q1 2019 in Review

Proxima Capital Management sold out of Puma Biotechnology (PBYI) in Q1 2019, closing a stake of 52,000 shares — an estimated $1.06M sold.

Proxima Capital Management first reported a position in PBYI in Q1 2018 and held it in 4 quarters. The position peaked at $2.78M in Q2 2018. 158 funds tracked by Wall St. Rank hold PBYI as of Q1 2019.

  • Proxima Capital Management reported no remaining Puma Biotechnology position as of Q1 2019 after selling out during the quarter.
  • Proxima Capital Management sold 52,000 Puma Biotechnology shares in Q1 2019, an estimated $1.06M.
  • Proxima Capital Management first reported a position in Puma Biotechnology in Q1 2018 and held it in 4 quarters.
  • Proxima Capital Management's Puma Biotechnology position peaked at $2.78M in Q2 2018.
  • 158 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2019.

Based on Proxima Capital Management's 13F filing for Q1 2019, filed 15 May 2019.